Muscular Dystrophy Cooperative Research Centers
The summary for the Muscular Dystrophy Cooperative Research Centers grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.
Muscular Dystrophy Cooperative Research Centers: Note: The following website has been established as an information resource for this RFA: http://www.niams.nih.gov/rtac/funding/grants/muscular_dystrophy_2004.htm The information will be updated periodically. The purpose of this Request for Applications (RFA) is to establish Muscular Dystrophy Cooperative Research Centers (MDCRCs),in order to increase basic and clinical research on all forms of muscular dystrophy. The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS),the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Child Health and Human Development (NICHD)invite applications for MDCRCs that promote side-by-side basic, translational, and clinical research; provide resources that can be used by the national muscle biology and neuromuscular research communities; and provide training and advice about muscle diseases for researchers and physicians who provide initial diagnosis and treatment, including rehabilitation, care for cognitive and behavioral concerns, and therapy for other system complications. Taken together, the centers will constitute a cohesive program, the MDCRC Program, operating under guidelines for NIH cooperative agreements. The primary goal of this initiative is to establish research centers, each of which will bring together expertise, infrastructure and resources focused on major questions about muscular dystrophy. Centers should use innovative research designs and state-of-the-art technologies. Achieving high levels of expertise and resources may require multi-institutional consortia. Centers are expected to provide an environment and core resources that will enhance collaborations of established basic, clinical, and behavioral science investigators to study muscular dystrophy research questions. Further, the environment should promote cross-disciplinary research training. Each center should develop in accordance with available expertise, interests, and resources, but should also be responsive to national needs related to muscular dystrophy. Although the types of activities that should be included are indicated in these guidelines, specific approaches to accomplish them are left to applicants. In addition to the self-contained activities of individual centers, the MDCRCs will collaborate with other centers, overseen by a Steering Committee involving representation from each center and from NIH. The centers will be funded through NIH Cooperative Agreements with the goal of maximizing collaborative utilization of the unique resources in infrastructure, expertise, and clinical recruitment that will be created. This is a re-issuance of RFA AR-03-001, Muscular Dystrophy Cooperative Research Centers. In FY 2003, NIAMS, NINDS, and NICHD awarded grants supporting three MDCRCs based on responses to the earlier RFA (see http://www.niams.nih.gov/ne/press/2003/10_14.htm) Investigators interested in applying for support of muscular dystrophy research using mechanisms other than this RFA should see NIH PAS-01-041, Therapeutic and Pathogenic Approaches for the Muscular Dystrophies at http://www.niams.nih.gov/rtac/funding/grants/pa/pas_01_041.pdf.
|Federal Grant Title:||Muscular Dystrophy Cooperative Research Centers|
|Federal Agency Name:||National Institutes of Health|
|Type of Opportunity:||Discretionary|
|Funding Opportunity Number:||RFA-AR-04-008|
|Type of Funding:||Cooperative Agreement|
|CFDA Descriptions:||Arthritis, Musculoskeletal and Skin Diseases Research 93.853 Extramural Research Programs in the Neurosciences and Neurological Disorders|
|Current Application Deadline:||No deadline provided|
|Original Application Deadline:||Aug 26, 2004|
|Posted Date:||Mar 23, 2004|
|Creation Date:||Mar 23, 2004|
|Archive Date:||Oct 14, 2004|
|Total Program Funding:|
|Maximum Federal Grant Award:|
|Minimum Federal Grant Award:|
|Expected Number of Awards:|
|Cost Sharing or Matching:||No|
- Applicants Eligible for this Grant
- City or township governments Special district governments Independent school districts Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Small businesses Others (see text field entitled "Additional Information on Eligibility" for clarification) State governments County governments
- Link to Full Grant Announcement
- Information not provided
- Grant Announcement Contact
- If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster FBOWebmaster@OD.NIH.GOV NIH OER Webmaster
- More Grants from the National Institutes of Health
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Administrative Resource...
- • Integrative Neuroscience Initiative on Alcoholism (INIA) Consortia Research Resource (U24)...
- • New Cohorts for Environmental Exposures and Cancer Risk (CEECR; UG3/UH3 Clinical Trial Not...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH2/UH3 Clinical ...
- • Assay Validation of High Quality Markers for Clinical Studies in Cancer (UH3 Clinical Tria...